T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,194,812 Ascendis Pharma A/S ADRs as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 8,194,812 ADRs of Ascendis Pharma A/S, representing 12.4% of the class.
- Sole voting power: The filing disclosed sole voting power over 7,767,048 shares, with zero shared voting power reported.
- Sole dispositive power: T. Rowe Price Investment Management holds sole dispositive power over all 8,194,812 shares, with no shared dispositive power.
- T. Rowe Price Capital Appreciation Fund interest: According to the filing, T. Rowe Price Capital Appreciation Fund holds an interest in 3,951,747 of the reported shares, representing 6.0% of the class.
- Event date: The date of event requiring this filing was September 30, 2026.
- Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (type "IA"), organized in Maryland, with offices at 1307 Point Street, Baltimore, MD 21231.
T. Rowe Price Investment Management Discloses Large ADR Position in Ascendis Pharma
T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to Schedule 13G disclosing that, as of September 30, 2026, it beneficially owned 8,194,812 American Depositary Receipts (ADRs) of Ascendis Pharma A/S (CUSIP 04351P101), equal to 12.4% of the class. The filing was signed by Ellen York, Vice President, and dated November 16, 2026. Ascendis Pharma A/S is headquartered at Tuborg Boulevard 12, Hellerup, DK-2900, according to the filing.
The filing reports that T. Rowe Price Investment Management holds sole voting power over 7,767,048 shares and sole dispositive power over the full 8,194,812 shares. Shared voting and shared dispositive power are each reported as zero. The filing identifies one client fund with an individually notable stake: T. Rowe Price Capital Appreciation Fund, for which T. Rowe Price Investment Management serves as investment adviser, holds an interest in 3,951,747 shares, representing 6.0% of the class.
Regarding the nature of the holdings, the filing states that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further states that T. Rowe Price Investment Management "expressly denied" being the beneficial owner of the securities for purposes of this Schedule 13G filing. Clients, or their custodians and trustee banks, retain the right to receive dividends and proceeds from sales, with any delegated discretionary authority revocable in whole or in part at any time, according to the filing.
What Was Disclosed
T. Rowe Price Investment Management, Inc. disclosed beneficial ownership of 8,194,812 Ascendis Pharma A/S ADRs, or 12.4% of the class, as of September 30, 2026, via Amendment No. 2 to Schedule 13G filed November 16, 2026.



Please wait processing your request...